Next Article in Journal
Pathogenic or Therapeutic Extracellular Vesicles in Rheumatic Diseases: Role of Mesenchymal Stem Cell-Derived Vesicles
Next Article in Special Issue
Differential Sarcomere and Electrophysiological Maturation of Human iPSC-Derived Cardiac Myocytes in Monolayer vs. Aggregation-Based Differentiation Protocols
Previous Article in Journal
Circadian Rhythm Neuropeptides in Drosophila: Signals for Normal Circadian Function and Circadian Neurodegenerative Disease
Previous Article in Special Issue
Bioethics of Clinical Applications of Stem Cells
Review

Induced Pluripotent Stem Cell Modeling of Gaucher’s Disease: What Have We Learned?

1
Department of Biomedical Sciences and Medicine, University of Algarve, Faro 8005-139, Portugal
2
Center for Biomedical Research, University of Algarve, Faro 8005-139, Portugal
3
Clínica EUGIN, Barcelona 08028, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Maurizio Muraca
Int. J. Mol. Sci. 2017, 18(4), 888; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18040888
Received: 28 March 2017 / Revised: 17 April 2017 / Accepted: 18 April 2017 / Published: 21 April 2017
(This article belongs to the Special Issue Stem Cell Research)
Gaucher’s disease (GD) is the most frequently inherited lysosomal storage disease, presenting both visceral and neurologic symptoms. Mutations in acid β-glucocerebrosidase disrupt the sphingolipid catabolic pathway promoting glucosylceramide (GlcCer) accumulation in lysosomes. Current treatment options are enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). However, neither of these approaches is effective in treating the neurological aspect of the disease. The use of small pharmacological compounds that act as molecular chaperones is a promising approach that is still experimental. In recent years, an association between GD and Parkinson like synucleinopathies has been discovered. Since 1992, a number of mouse models of GD have been the developed and partially reproduce phenotype of the disease. More recently, the discovery of direct reprograming has allowed the derivation of induced pluripotent stem cells (iPSc) from fibroblasts obtained from GD patients. iPSc can be expanded indefinitely in vitro and differentiated to macrophages and neurons, the main relevant cell types involved in GD. In this work, we review iPSc models of GD and summarize what we have learned from this system. View Full-Text
Keywords: lysosomal storage disease; Gaucher’s disease; glucocerebrosidase; induced pluripotent stem cells; chaperone therapy lysosomal storage disease; Gaucher’s disease; glucocerebrosidase; induced pluripotent stem cells; chaperone therapy
MDPI and ACS Style

Santos, D.M.; Tiscornia, G. Induced Pluripotent Stem Cell Modeling of Gaucher’s Disease: What Have We Learned? Int. J. Mol. Sci. 2017, 18, 888. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18040888

AMA Style

Santos DM, Tiscornia G. Induced Pluripotent Stem Cell Modeling of Gaucher’s Disease: What Have We Learned? International Journal of Molecular Sciences. 2017; 18(4):888. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18040888

Chicago/Turabian Style

Santos, Dino M., and Gustavo Tiscornia. 2017. "Induced Pluripotent Stem Cell Modeling of Gaucher’s Disease: What Have We Learned?" International Journal of Molecular Sciences 18, no. 4: 888. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18040888

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop